Further validation of the diagnostic accuracy of NCF2, MYO1F, S1PR4, and FCN1 in STEMI patients showed that these four hub genes could also act as accurate biomarkers to discriminate STEMI patients from stable CAD patients. This evidence concerns the gene NCF2 and coronary artery disorder.